NPPA Mandates Prominent Display Of Revised Prices For 137 Anti-Cancer Drugs

The National Pharmaceutical Pricing Authority (NPPA) has directed all manufacturers, hospitals, and retailers to strictly implement <b>trade margin rationalisation</b> on 137 non-scheduled anti-cancer drugs. Following the notification of revised prices effective November 9, institutions must prominently display updated price lists at their premises and on official websites. State drug controllers are tasked with monitoring compliance to ensure patients receive the benefits of revised maximum retail prices. Any instances of overcharging will face proceedings under the <b>DPCO 2013</b> provisions. Patients can report grievances regarding medicine availability or pricing through the 'Pharma Sahi Daam' portal, with state authorities required to submit action taken reports by November 16.